Impact of diagnostic labels and management benefit-to-harms information for low-risk prostate pathology

3 Aug

Bell, K. J. L., Boroumand, F., Wu, Z., Wilt, T. J., Parker, L., Millar, J., Smith, J., McCaffery, K., Brodersen, J. B., Dahm, P., Delahunt, B., Glasziou, P., Warden, A., Diller, L., van Rensburg, C., & Nickel, B. (2026). Impact of diagnostic labels and management benefit-to-harms information for low-risk prostate pathology. Journal of the National Cancer Institute, djag248. Advance online publication. https://doi.org/10.1093/jnci/djag248

Disease labelsProstateOvertreatment

Mali Dunn

Mind the Gap: Impact of New Labels on Public Perceptions and Calculated Risk of Adverse Outcomes after a Melanoma In Situ Diagnosis-A Secondary Analysis of an Online Randomized Experiment

Impact of diagnostic labels and management benefit-to-harms information for low-risk prostate pathology

Mind the Gap: Impact of New Labels on Public Perceptions and Calculated Risk of Adverse Outcomes after a Melanoma In Situ Diagnosis-A Secondary Analysis of an Online Randomized Experiment

Association between risk-related lifestyle factors, screening adherence and breast cancer incidence: a decomposition analysis